Cost-effectiveness analysis of community-acquired pneumonia therapeutic treatments
doi: 10.3969/j.issn.1006-0111.2014.04.023
- Received Date: 2013-05-08
- Rev Recd Date: 2013-11-12
Abstract: Objective To evaluate the pharmacoeconomics effectiveness of two community-acquired pneumonia therapeutic treatments, and provide guidance for rational drug use. Methods Two therapeutic schemes were analyzed through cost-effectiveness analysis.Result Between the two treatments, the total cost by using moxifloxacin alone (Group A) was 4 092.75 RMB, while that of using azithromycin and cefuroxime (Group B) combined was 3 306.83 RMB; the effective rates were 88.89% and 85.71%, respectively; the incremental cost for each effect unit of these two treatments was 46.04 RMB and 38.58 RMB. Conclusion It is more economical and reasonable to use azithromycin and cefuroxime combination for the therapeutic treatment of community-acquired pneumonia.
Citation: | ZHANG Lifang, XU Lan. Cost-effectiveness analysis of community-acquired pneumonia therapeutic treatments[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 315-317. doi: 10.3969/j.issn.1006-0111.2014.04.023 |